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Abstract 
Microarray data of 1,056 breast tumors from NCBI’s GEO database were collected and analyzed. 
The goal was to discover microarrays most similar to a potentially novel subtype of breast cancer 
characterized by low claudin expression. Claudins form tight junctions, which regulate cell-cell 
movement of solutes and ions; faulty tight junctions have been correlated with cancer metastasis. 
Results showed little support for a Claudin-Low cluster. Nine clusters were found, when 5-6 were 
expected. These additional clusters may reveal novel subtypes. 
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1. Introduction 
Microarray technology allows the analysis of global gene expression in cell samples of different 
cell types or exposure to varying treatment conditions. One practical application of this involves the field 
of cancer research. Herschkowitz et al. (2007) profiled the expression patterns of breast cancers from 
women and compared them to tumors derived from a variety of mouse breast cancer models. During 
this process, a new, rare, and potentially dangerous subtype was discovered. This new subtype was 
characterized by low expression of genes involved in tight junctions and cell-cell adhesion 
(Herschkowitz, et al., 2007). The subtype was referred to as the “Claudin-Low” subtype since several 
Claudin family members segregated among this group of low expressing genes. Claudin proteins form 
intercellular tight junctions between cells, which control the paracellular flow of molecules. 
Intracellularly, tight junctions are the docking site for signaling molecules, such as growth factor 
receptors, as well as actin fibers that are critical for the cytoskeleton. Defective tight junctions can cause 
unnatural cell proliferation and may increase the metastatic potential of tumor cells, which are 
hallmarks of malignant forms of cancer. Reduced intercellular adhesion may permit carcinoma cells to 
migrate in other areas of the body, which makes them especially dangerous, since tumor metastasis is 
associated with the high morbidity of cancer. 
However, the Claudin-Low subtype was identified in only about 6% of microarrays in the data 
used in the Herschkowitz (2007) paper. 
In order to confirm that tumors exhibiting the Claudin-Low subtype exist outside of the original 
data set considered, and to potentially discover more tumors that demonstrate the Claudin-Low 
subtype, a larger data set was analyzed using a similar approach. Microarray data of 1,056 breast tumors 
from NCBI’s Gene Expression Omnibus database were downloaded and analyzed using various data 
mining techniques. The discovery of multiple microarrays exhibiting similar gene expression profiles to 
Claudin-Low tumors would confirm the existence of this subtype, and a gene classifier could be 
developed to identify tumors of this type. The primary tool used for this analysis was hierarchical 
clustering supplemented with various filters and information enhancement algorithms. Additionally, 
once a Claudin-Low-like expression pattern was discovered, different distance metrics were used to 
compare the microarrays, to this expression pattern, in order to find the most similar tumor samples. 
Hierarchical clustering using a simple threshold of gene variation as a filter showed little support for a 
distinctly Claudin-Low cluster in the larger cohort of microarrays. This is not conclusive evidence that 
Claudin-Low tumors are nonexistent, and several factors may explain why a distinct cluster of Claudin-
Low tumors was not identified in our current analysis. One reason may be an ascertainment bias. Since 
Claudin-low tumors can show a distinct metaplastic morphology when compared to other tumors of the 
breast (Hennessy, et al., 2009), Claudin-Low tumors may have been inadvertently excluded from studies 
focused on analyzing breast adenocarcinomas. Second, because the microarrays were performed on 
bulk tumor cells, it is possible that Claudin-Low cells make up a fraction of cells in a heterogeneous 
sample. If they contribute to only a minor proportion of cells in the tumor, then their expression 
signature would be swamped by the expression of the majority of tumor cells. Claudin-Low cells show 
similar expression profiles to cells with enhanced “tumorigenicity” (Al-Hajj et al., 2003), which may be 
indicative of cancer stem cell phenotype (Hennessy, et al., 2009) and chemotherapy resistance (Li, et al., 
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2008). So, although the results do not support a distinct subtype, understanding the biology of cells with 
the Claudin-Low phenotype may still have broad implications for more effective treatment of aggressive 
breast cancers. While a definitive Claudin-Low subtype was not extracted from the data, nine distinct 
clusters were found, when five were expected. These results may help to further stratify previously 
identified subtypes into subcategories with distinct biology and clinical outcomes. 
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2. Background 
2.1. Gene Expression  
The central dogma of molecular biology illustrates the flow of biological information between the three 
major bio-molecules: DNA, RNA, and protein. Generally, DNA is used to create RNA, which is then used 
to create proteins; this is shown in Figure 1. 
 
 
Figure 1 – The Central Dogma of Molecular Biology. Diagram shows the normal flow of genetic 
information from DNA to RNA to protein. Profiles of RNA types expressed in tumor cells were analyzed in 
this project. (Horspool) 
In order to convert from one bio-molecule to another, a complex process is required. The 
production of RNA from DNA is known as transcription, and the production of protein from DNA is 
known as translation. The necessity of these conversions is due to the different roles that each bio-
molecule plays as a result of its structure. 
2.1.1. Bio-molecules Overview 
DNA is made up of two anti-parallel strands (same information, opposite directions), arranged in 
the shape of a double helix and connected through hydrogen bonds. Each strand consists of two ends: 
the 5’ end and the 3’ end; the number of each end corresponds to the number of the terminal carbons 
on the nucleotide. Each strand is also comprised of a sequence of four nucleotides: adenine (A), guanine 
(G), cytosine (C), and thymine (T). These nucleotides have specific pairing behaviors amongst each other: 
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adenine will bond with thymine, and guanine will bond with cytosine; this is referred to as 
complementary base pairing. 
These properties of DNA allow it to be a suitable medium for long-term storage of genetic 
information. Being double stranded provides many benefits: the molecule is more stable against 
physical forces and chemical degradation, replication can occur easily and accurately with either strand 
as a template (due to complementary base pairing), and transcription can be carried out faster since 
either strand of the DNA can be used as a template (Freeman, 2005). 
RNA is a nucleic acid like DNA, but there are three main differences. First, RNA is usually single 
stranded and shorter than DNA. This means that RNA is able to adopt structures other than the double 
helix found in DNA, allowing it to act as a functional molecule. Secondly, RNA contains a ribose sugar 
(instead of deoxyribose) as the backbone. This causes RNA to be much more reactive than DNA, because 
the attached group is a hydroxyl (-OH) instead of the more stable hydrogen (Freeman, 2005). Also, RNA 
contains no thymine. This is controlled during transcription, discussed in section 2.1.2. With respect to 
this project, not all the information residing in DNA is transcribed into RNA, so the profile of RNA 
molecules varies from cell to cell, and between cells at different stages of tumor formation. 
Proteins are the main functional molecules in cells. They perform diverse functions, including 
defense, movement, catalysis, signaling, structure, and transport (Freeman, 2005). All these various 
functions are made possible by the numerous conformations that a protein can form. Protein structure 
can be described in four levels of complexity: primary structure, secondary structure, tertiary structure, 
and quaternary structure. The primary structure is the linear sequence of the amino acids forming the 
proteins (instead of nucleotides, amino acids are the building blocks of proteins). The secondary 
structure is the arrangement or folding of the peptide’s structure due to local interactions of amino 
acids; the three possible conformations are helices, sheets, and turns. The tertiary structure is the three-
dimensional structure of the polypeptide (including interactions amongst multiple peptides). Finally, 
quaternary structure describes the arrangement and interaction of multiple polypeptides; it is possible 
for proteins to be made up of multiple polypeptide chains (Voet et al., 2008). 
2.1.2. Transcription 
In the process of transcription a DNA sequence is used as a template to output a functional 
mRNA. The process occurs from the 3’ to 5’ direction on the template DNA strand so that the RNA chain 
can grow in the 5’ to 3’ direction; this occurs in the nucleus of the cell. In eukaryotes, RNA Polymerase II 
binds to General Transcription Factors (GTF), which bind to the promoter region (usually downstream of 
a TATA chain of nucleotides). After this binding, RNA Polymerase II then continues down the 5’ direction 
of the template strand, building the RNA on the 3’ end. RNA Polymerase II continues to travel down the 
DNA until it reaches the end. It is important to note that the template strand of DNA being used to 
create the transcript RNA will have sequences that are complementary to the transcript RNA formed 
(Griffiths et al., 2008). 
The RNA transcript is significantly different from the DNA sequence it is built from. When an A is 
encountered in the template strand, rather than pairing it with a T in the new mRNA, a different amino 
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acid, uracil (U), is used. Aside from replacing all T’s with U’s, transcription also goes through numerous 
processing steps that modify the transcript RNA so that it is not just a DNA clone. These processing 
events occur as RNA Polymerase II travels along the template DNA. One modification is the addition of a 
cap at the 5’ end of the transcript. The cap prevents RNA degradation and is used to initiate translation. 
Another modification is the terminating RNA transcription. This occurs when a sequence that contains 
the nucleotides AAUAAA or AUUAAA shows up on the 3’ end of the transcript RNA. An enzyme 
recognizes this site and proceeds to cut it. Finally, the last two processing events go hand-in-hand: 
splicing and removal of introns. In eukaryotic DNA, there are sequences known as introns and exons. 
Exons are regions containing nucleotides that code for amino acids while introns are regions containing 
nucleotides that are not translated. Therefore, during transcription, all the introns are usually removed, 
and exons are aligned next to each other. Additionally, it is possible for the arrangement of exons to 
differ. For example, if a gene has three exons, it is possible that one transcript RNA will contain exons 1 
and 2 while another transcript may contain only exons 1 and 3. This is known as alternative splicing and 
is what allows a single gene to code for multiple proteins (Griffiths et al., 2008). 
2.1.3. Translation 
Unlike DNA replication and transcription, translation travels down its template strand (an 
mRNA) in the 5’ to 3’ direction and occurs in the cytoplasm (except for the translation of secretory 
proteins, which occurs within the endoplasmic reticulum (ER)). The key players of translation are the 
ribosome and tRNA. Ribosomes attach to the cap of the mRNA and proceed down the mRNA until it 
finds a nucleotide start sequence (AUG). When it finds this sequence, a tRNA containing the 
complementary sequence will attach to the ribosome and drop off a methionine molecule. This will 
proceed with subsequent triplets of nucleotides until a stop sequence is reached on the mRNA (UAA, 
UAG, UGA). Once this stop sequence is reached, the ribosome is released from the mRNA in order to 
find another mRNA to translate. Figure 2 shows which amino acid is coded by each nucleotide triplet 
(Griffiths et al., 2008). 
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Figure 2 – Graphic Illustrating the Universal Genetic Code. The table shows a list of 
which amino acid is encoded by each nucleotide triplet. (Cooper & Hausman, 2007) 
 
2.1.4. Expression Regulation 
In eukaryotes, there are many methods to regulate gene expression. With respect to this 
project, the main category of gene regulation that we are concerned with is transcriptional regulation. 
Normally, eukaryotic DNA does not undergo transcription. This is because most genes are packaged in a 
tightly wound structure known as chromatin. The DNA is wound tightly around histone octamers in 
structures known as nucleosomes. In order to unwind the chromatin, complexes add or remove 
molecules at the histone tails protruding from the nucleosomes. Another transcription regulation tool is 
the enhancer sequences. These regions allow multiple transcription factors to bind, forming 
enhanceosomes, which are large protein complexes that activate transcription mainly through reshaping 
the DNA so that RNA Polymerase II can bind and travel along it. Analyzing the levels of mRNA in a cell 
allows one to estimate what genes are actually being expressed (translated into protein), and infer the 
biology of the cell.  
2.2. Epithelial Cell Development 
An example of epithelial cell development can be found in skin cells. In skin, pluripotent 
epidermal stem cells are situated in the bulb of hair follicles. Above this layer are more specialized stem 
cells; these cells are committed to becoming epidermal cells and are found in the basal layer of the skin. 
The next layer is the spinosum layer, and this houses the transit-amplifying cells. Above the spinosum is 
the granular layer, which contains numerous cytokeratin-filled granules. Accumulation of cytokeratin by 
skin cells causes the skin cells to lose their structure, forming the outer layer of the corneum (top-most 
layer of skin) (Majumder, 2009, p. 4). 
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Early studies by DeOme (1959) showed that a subset of mammary cells can act as stem cells to 
repopulate the mammary gland. Although the hierarchy of cells in the mammary gland, or the epithelial 
structures that comprise the other organs of the body, is less clearly defined than skin, the development 
of these diverse tissues likely involve analogous mechanisms. 
2.3. Cancer Biology 
Cancer is characterized by uncontrolled cell growth. This uncontrolled cell growth is generally 
the result of DNA mutations that affect genes regulating the cell cycle. Some mutations that lead to this 
phenotype are mutations that cause cells to: ignore apoptosis signals, self-produce growth factors, 
ignore growth inhibition signals, and fail to differentiate. Although some viruses are able to cause 
tumors by mutating human DNA, the majority of tumors are caused by radiation and chemical 
carcinogens (Cooper & Hausman, 2007). 
The specific mechanics behind tumor behaviors are still being elucidated today. At the moment, 
there are two major competing models for the development of cancer: the stem cell theory of cancer 
and the de-differentiation theory of cancer (Majumder, 2009, pp. 7-8). 
2.3.1. Stem Cell Theory of Cancer 
Cancer is a problem of developmental biology (Majumder, 2009, pp. 2-3). In normal 
development, the two main phases are expansion and determination (Majumder, 2009, p. 3). After 
fertilization of the egg, the initial stem cell will divide symmetrically for the first five to six divisions 
(Majumder, 2009, p. 3). The daughter cells produced during these divisions are completely totipotent, 
thus during this expansion phase, the number of embryonic stem cells expands (Majumder, 2009, p. 3). 
Once this expansion is completed, the cells move into the determination phase; during this phase, 
divisions occur asymmetrically. As a result of the asymmetrical divisions, one of the daughter cells 
remains a stem cell, while the other daughter cell begins to travel down the path of differentiation, 
slowly losing its stem cell characteristics (Majumder, 2009, p. 4). The stem cell theory of cancer states 
that the cause of cancer lies in a failure to properly complete such a progression (Majumder, 2009, p. 4), 
leaving immortalized cells with stem-like properties as a seed for the tumor. 
Although the cells in cancer tissue are mostly undifferentiated and do not mature properly, the 
same types of cells are observed in both normal and cancer tissues: stem cells, transit-amplifying cells, 
and terminally differentiated cells (Majumder, 2009, p. 4). The difference between the two tissues is the 
quantity of the different cell types; more specifically, the quantity of transit-amplifying cells (Majumder, 
2009, p. 4). In normal cells, the transit-amplifying cells divide a finite number of times before becoming 
terminally differentiated cells, which are unable to divide further. However, in cancer cells, the transit-
amplifying cells divide without approaching a terminally differentiated state, thus resulting in unnatural 
accumulation of this cell type (Majumder, 2009, p. 4). The physical product of this can actually be seen 
(a tumor), but it does not necessarily explain how metastasis occurs. Cancer stem cells are this theory’s 
solution to the metastasis issue (Majumder, 2009, pp. 13-15). 
Although recent findings in cancers of various tissues show some support for the stem cell 
theory of cancer, the strongest support for this theory come from teratocarcinomas (cancers in germ 
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tissue) (Majumder, 2009, p. 9). Since germ cells can differentiate into both the embryo, and yolk sac and 
placenta, they are true stem cells (fully totipotent). In 1964, Leoy Stevens transplanted normal testicular 
germ cells into unnatural locations in a mouse model; teratocarcinomas appeared at these sites, 
suggesting that normal stem cells can transform into cancer cells if removed from their native 
environment (Majumder, 2009, pp. 9-10). Another experiment that showed strong support for this 
theory was conducted in skin cells. A reliable way to induce cancer in the skin involves a 2-step process 
of initiation and promotion (Majumder, 2009, pp. 12-13). In initiation, the skin is exposed to 
Benz(o)pyrene, which binds to DNA in skin cells, permanently altering the genes. Cancer will not rise 
until these cells are treated with phorbol ester, which promotes the damaged cells to proliferate. In this 
specific experiment, the time elapsed between initiation and promotion was varied, and the results 
were surprising. Regardless of the time elapsed, cancer will always result after the promotion 
procedures (assuming initiation occurred). Since skin cells shed every 2 – 3 weeks in mice, the initiation 
must have affected the stem cells responsible for replacing the skin cells (Majumder, 2009, pp. 12-13). 
2.3.2. De-differentiation Theory of Cancer 
The de-differentiation theory of cancer was the standard model for cancer formation until the 
stem cell theory recently re-immerged. This theory states that cancers occur when mature cells return 
to a less differentiated form as a result of external stimuli like chemicals, parasites, and viruses 
(Majumder, 2009, p. 8). Current clinical prognosis of cancers is determined by assigning a tumor grade 
by specially trained surgical pathologists. Tumor grade is largely based on the level of differentiation of a 
tumor, indicated by the morphology of the cancer cells. Nevertheless, the molecular basis for tumor 
differentiation is largely undefined. Intriguingly, the Weinberg lab (Mani, et al., 2008) described a series 
of experiments that may help to unify the stem cell and de-differentiation models. Through an 
epigenetic process called epithelial to mesenchymal transition (EMT), a normal cellular transformation 
that occurs during development and wound healing where epithelial cells acquire stem call 
characteristics. This process is governed by a series of transcriptional repressor proteins, including Snail, 
Slug, and Twist, which were first described in Drosophila developmental pathways. Genes encoding 
these proteins show elevated transcript levels among Claudin-Low tumors (Herschkowitz, et al., 2007). 
More importantly, the targets of these transcriptional repressors include the low expressing genes that 
co-segregate with the Claudin genes in Claudin-Low tumors, leading us and others (Hennessy, et al., 
2009) to speculate that Claudin-Low tumor cells represent mammary epithelial precursor cells or cells 
that have undergone an EMT. 
2.3.3. Breast Cancer 
Breast cancer starts in the tissues of the breast and can be classified in numerous ways. Current 
clinical practice relies heavily on the expression of several growth factor receptors, including the 
estrogen and progesterone receptors, and HER2/ERBB2. The expression of these proteins (or their 
absence), along with pathological evaluation, and whether a tumor has metastasized locally or distantly, 
will all be considered by a physician when deciding a therapeutic regimen to recommend to a patient. 
An alternate way to classify breast cancers that is emerging is to categorize them into subtypes based on 
their gene expression profiles. The type of breast cancer this project is focused on, Claudin-Low, would 
be described as a “Triple Negative” (none of the three receptor proteins is expressed) by standard 
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clinical criteria (Herschkowitz, et al., 2007). Triple Negative tumors generally have a poor clinical 
outcome, and no specific targeted therapies exist, so these patients are typically treated with harsh 
chemotherapies. The current subtypes of breast cancer that have been confirmed by gene expression 
signatures are Luminal A, Luminal B, Normal Breast-Like, ERB2-Overexpressing, and Basal Epithelial-Like 
(Majumder, 2009, p. 93); these subtypes vary in terms of prognoses for metastasis-free or overall 
survival (Majumder, 2009, p. 93). 
2.3.4. Tight Junctions 
 Tight junctions (Figure 3) regulate the movement of solutes and ions between adjacent cells 
through passive, electro-osmotic gradient-driven transport (Gonzalez-Mariscal, 2006, p. 33). The 
gradients are typically a side-effect of active transports and external exposures like food consumption 
(Gonzalez-Mariscal, 2006). Three attributes that are variable in tight junctions are electrical 
conductance, size, and charge selectivity (Gonzalez-Mariscal, 2006, p. 34). Conductance is the most 
variable and is classified in five orders of magnitude from leaky to tight; leaky epithelium is 
characterized by having at least half of their total conductance occurring through tight junctions 
(Gonzalez-Mariscal, 2006, p. 34). The size of tight junctions vary, junctions of epithelial cells generally 
range from 7 – 15 Å (Gonzalez-Mariscal, 2006, p. 34). Lastly, selectivity is defined as the permeability 
ratio of sodium to chloride; most epithelia are cation-selective, meaning that the sodium permeability is 
higher than the chloride’s (Gonzalez-Mariscal, 2006, p. 34). 
 
Figure 3 – Conceptual Illustration of Tight Junctions. (Bryant & Mostov, 2008) 
 
 The two kinds of proteins that form or interact with tight junctions are cytoplasmic proteins and 
membrane proteins (Gonzalez-Mariscal, 2006, p. 118). The cytoplasmic proteins are further divided into 
two groups: PDZ domain-containing adaptor proteins and non-PDZ domain-containing adaptor and 
signaling proteins (Gonzalez-Mariscal, 2006, p. 118). Claudins, JAMs, occludins, and Crumbs constitute 
the membrane proteins; occludins and claudins are linked to the regulation of epithelia proliferation, 
while JAMs and Crumbs interact with signaling complexes controlling epithelial polarization (Gonzalez-
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Mariscal, 2006, p. 110). Furthermore, the intertwining of some of these membrane proteins between 
adjacent cells form physical barriers that further regulate the movement of solutes and ions between 
cells (Gonzalez-Mariscal, 2006, p. 34). Since tight junctions are not very adhesive, they work in 
conjunction with the adherens junctions and desmosomes, forming junctional complexes between cells 
(Cooper & Hausman, 2007) (Figure 3). 
2.3.5. Claudin 
Contrary to the behavior of occludins and JAMs, claudin expression is required for the formation 
of tight junctions in cells (Gonzalez-Mariscal, 2006, p. 117). The claudin family of proteins consists of at 
least 24 members in humans and mice, with each member varying in frequency and localization 
throughout the body (Gonzalez-Mariscal, 2006, p. 37). These proteins cross the cell membrane four 
times (Figure 4) and range in size from 20 – 25kDa (Gonzalez-Mariscal, 2006, p. 34). The most 
distinguishing characteristics of claudins are the presence of a WGLWCC motif of conserved amino acids 
located in the first loops away from the cytoplasm, and termination of the proteins in PDZ binding 
motifs, which bind PDZ domains in cytoplasmic proteins like ZO-1 (Gonzalez-Mariscal, 2006, p. 34). 
Proteins that are most homologous to claudins are the membrane proteins of the eye lens (MP2)), 
epithelial membrane proteins (EMP), and peripheral myelin proteins (PMP) (Gonzalez-Mariscal, 2006, p. 
36). 
 
Figure 4 – Diagram of Claudin Structure. Figure shows Claudins as transmembrane 
proteins that pass the membrane four times. (Morin, 2005). 
 
 The primary cause for the variances in tight junction permeability has been attributed to varying 
concentrations of the different claudins in the tight junctions (Gonzalez-Mariscal, 2006, p. 37). In one 
experiment, where claudin-1 expression was promoted in low resistance MDCK cells, the cells exhibited 
higher cell-cell adhesion, which suggests increased electrical resistance across the epithelium (Gonzalez-
Mariscal, 2006, p. 37). In another experiment, claudin-2 expression was promoted in high resistance 
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MDCK cells, but the cells turned out leakier than before (Gonzalez-Mariscal, 2006, p. 37). When claudin-
5 was knocked out from mice, the brain tissues between the wild type and mutant mice exhibited 
drastic differences. When molecular markers were passed through the tissues, the wild type tissues 
retained markers from 68kDa to 562Da while the mutant tissues became leaky up to 562Da but 
restricted the next highest marker (1862Da) (Gonzalez-Mariscal, 2006, p. 39). Despite their conflicting 
behaviors, claudins are still vital in the proper regulation of tight junctions.  
2.3.6. Claudins, Tight Junctions, and Cancer 
Studies have shown a correlation between lowered expression levels of tight junction proteins 
and increased rates of cancers; this suggests that tight junction proteins may be involved in controlling 
cell growth and differentiation  (Gonzalez-Mariscal, 2006, p. 96). Additionally, the disruption of tight 
junctions is characteristic of malignant and metastatic cancers (Gonzalez-Mariscal, 2006, p. 126). Further 
evidence linking tight junctions and cancers can be seen in the microvessls, small blood vessels that 
branch out from the main arteries, which feed tumors; these vessels often have reduced occluding and 
claudin expression (Gonzalez-Mariscal, 2006, p. 120). 
2.4. Microarray Technology 
 mRNA quantities in cells are a good indicator of gene expression, since mRNA is used as a 
template for the creation of proteins. Microarrays are a method to measure gene expression through 
mRNA quantities. A microarray consists of thousands of cDNA sequences hybridized to different wells on 
a glass slide or a biochip. Copy DNA (cDNA), are DNA sequences that have been derived from mRNA and 
therefore do not contain non-coding introns (although non-coding un-translated regions UTRs present in 
mRNAs may be represented on the chip). The construction of cDNA allows mRNA of opposite sense to 
attach to it. A biochip is a non-porous material containing miniaturized wells. Microarrays that use the 
biochip approach can be much smaller and can be created using several technologies not usable 
otherwise, including ink jetting and photolithography. Using these advanced fabrication techniques 
biochips are also able to have smaller wells, closer together. The number of wells per area is termed well 
density. Biochips can be built to have high enough well density such that the entire human genome can 
be represented in one chip (Freeman, 2005) 
 The following sample high-level procedure illustrates the theory behind the construction of 
microarrays and how they are used to quantify mRNA levels. First, a sample of the target cell’s total 
cellular mRNA is procured. This mRNA sample is labeled with a fluorescent marker. Another mRNA 
sample, from a population that the first will be compared to, is also taken and labeled with a different 
fluorescent color. In practice, the target mRNA sample is labeled with a red color fluorescence and the 
second mRNA sample with a green. Both of the mRNA samples are then hybridized to the biochip at the 
same time. After the hybridization process is finished and the excess (non-hybridized) mRNA is cleared 
from the biochip it can be scanned and data collected. This is called a “two color” microarray analysis. 
Another approach is to only hybridize one each of the two samples to two different biochips and only 
measure the intensity of the fluorescence; this is termed a “one color” microarray analysis. It is common 
to have a reference in a single color analysis, usually a sample taken from a common cell line, which is 
run under the same conditions, as the other samples being observed and is used to normalize the data 
between different runs. For example, if under one condition genes of the reference are at one level and 
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under another condition the same genes of the reference are seen to have a lower intensity the data 
from the second run should be normalized to the first runs reference numbers.  
After hybridization in a two color analysis, thereof ratio of the two labeled samples will reflect 
the abundance of transcript in a sample. A red color, or the color of the target mRNA, denotes an 
upregulation of the gene corresponding to the cDNA in that well under the conditions of the target 
sample as compared to the other sample. A green color, or the color of the second mRNA, denotes a 
downregulation of the gene corresponding to the cDNA in that well under the conditions of the target 
sample as compared to the other sample. A yellow color, or the combination of the two colors, denotes 
that both colored mRNAs hybridized to the same spot on the array, so the expression of the gene in 
both conditions is the same. A well with a black color after hybridization implies that neither sample’s 
mRNA hybridized to it, meaning the gene is not being expressed at the time of sample collection in 
either sample. These shades are measured using sensor technologies that will convert the fluorescence 
under each light frequency to a number. These numbers are combined to produce the raw data from a 
microarray. The data from a microarray has indirectly been shown to have a correlation with the 
amount of protein that is produced. For example, DeRisi et al. (1997) showed that microarray data 
collected from yeast corroborates up or down regulation of gene expression expectations under 
different conditions (Voet et al., 2008). 
 All microarray data used in this project was gathered using Affymetrix microarrays. The 
Affymetrix microarray is a single color microarray on a biochip created using photolithography. The 
cDNAs used on these biochips are 25-mer oligonucleotides arranged in perfect sense/mismatch pairs 
(Freeman, 2005). The difference between the perfect sense and mismatch genes are that the mismatch 
are the same as the perfect sense except for the 13th nucleotide. However, it has been shown that the 
information gained from the mismatch pairs is marginal (Bolstad et al., 2003). The Affymetrix microarray 
is measured using scanning confocal microscopes. All procedures involving Affymetrix microarrays have 
been automated, allowing for much more reproducible results that can be obtained more efficiently. 
Further, since the process has been automated, the there is less need for normalization, which may 
skew the data, especially for low signal levels.  
2.5. Computational Biology 
 Due to the large amount of genetic and gene expression information inherent in many large 
studies conducted by biologists and others interested in life sciences it is becoming more common to 
analyze those datasets using techniques from computer science. Data mining techniques can be used on 
data from biological experiments to detect patterns, expose similarities, and make predictions. As 
researchers have realized the potential of this sort of analysis on data, tools to reduce time and effort of 
this analysis have been created. Further, as computer analysis of biological data has become more 
prevalent, tools have been developed especially for this domain.  
In any area that data mining is applied, domain knowledge can promote better results through 
attribute selection and chosen form of analysis. Biology is no exception to this rule as several reviewed 
papers have shown machine learning techniques being applied to biological datasets. Hu et al. (2006) 
demonstrated that there are 306 intrinsic genes that affect breast cancer through attribute selection 
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techniques. Herschkowitz et al. (2007) showed that clustering, a form of computing similarities, can be 
used to analyze microarray data. Finally, Reyal et al. (2008) showed that classification techniques can be 
applied to gene expression information from microarrays.  
2.5.1. Tools in Computational Biology 
 The main tools used for this project are RMAExpress, Cluster 3.0, Java TreeView, and dChip. 
Specific details about these tools can be found in the methods section. 
2.5.2. Highlighted Techniques in Data Mining 
Any task in data mining can be generalized to the following flow: data storage/retrieval, data 
pre-processing, pattern discovery, pattern evaluation, and pattern usage. Many techniques and 
approaches can be employed in conjunction with each of these steps. Data pre-processing refers to any 
technique that prepares the data to make pattern recognition more manageable and produce better 
results without losing any of the information present in the original data. Pattern discovery techniques 
attempt to find patterns, given sets of data.  
Normalization is a technique that can be used to put numbers of an attribute onto a different 
scale. Examples of normalization include log normalization, where the logarithmic value, base two, is 
taken. Another, more advanced use of normalization would be to compare the reference gene values 
between two single color microarrays to obtain a normalization factor which can then be applied to the 
results, making them directly comparable. Although normalization does not change the intrinsic 
behavior of the data, it facilitates analysis of the data. 
In data sets where data for each attribute is not necessarily available it may be required that 
techniques to determine a value for missing attribute is applied. In any case, the best solution to issues 
of this nature is to attempt to gather the actual value for that instance in the data set. If this is not 
possible, the mode or mean of values in that attribute from other instances may be the best to give to 
missing values. Other options include assigning values based on other attributes, which may require 
domain experience, or to assign a set value to the missing attribute. However, in some cases this may 
bias the data and another approach should be investigated. Missing values can be treated as a separate 
value in some forms of pattern discovery.  
Attribute selection can be used to reduce the number of attributes that are present in a data 
set. The attributes that are selected should be the attributes that have the most effect on the outcome 
that is trying to be predicted. Generally, this means that attributes without much variation can be 
released from the data set as they do not help to classify an outcome and are not characteristic to any 
instance. Correlation based feature selection is one method that can be used to select only attributes 
which give the most information about the outcome. This method works by performing a heuristic 
search over subsets of attributes. The search gives the highest merit to a set of attributes which predict 
the target attribute the best but are also the most independent from each other (Witten 2005). 
Classification algorithms are used to determine which sets of attribute values predict which 
outcomes. This is a common approach in any data set where some outcome is recorded for each 
instance. The construction of decisions trees is an approach that attempts to determine the outcome 
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based on splitting the data by attribute value. Another technique is to mine association rules which find 
within the data that some set of attribute values is associated with another set of values. If rules are 
selected such that the set of values is associated with an outcome they can become classification rules, 
or rules that predict outcomes. Classification rules can also come from domain knowledge and be 
applied to a dataset to verify the class of an instance. 
Clustering algorithms can be used to measure similarity between instances. There are several 
methods used in clustering analysis. One of these methods is the k-means clustering algorithm which 
assigns some number of initial instances as initial cluster centers and then all of the most similar 
instances are assigned to that cluster. The mean values of each of those instances are calculated and 
that becomes the new cluster centroid, with the most similar instances being assigned to their new 
closest cluster centroid. This continues until the calculated mean value for each cluster is equal to the 
current point of the respective cluster centroid (Witten & Frank, 2005). Another method, termed 
incremental clustering, takes as input each instance and uses category utility to decide if it is more 
useful to make that input its own cluster, add it to another cluster or split another cluster into multiple 
clusters (Witten 2005).  
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3. Materials and Methods 
3.1. Materials 
3.1.1. Data 
 The data used for this project is the same data used in a recent meta-analysis of breast cancer 
expression data by Reyal et al. (2008). This data set consists of 1,056 microarrays of samples from the 
tumors of breast cancer patients. Each microarray consisted of fluorescence readings over 22,283 probe 
sets. A probe set is made up of various nucleotide sequences that are designed to attach to 
complementary sequences that correlate to known DNA sequences (GeneChip Mouse Expression Set 
430). The data is freely obtainable through NCBI’s Gene Expression Omnibus (GEO) data set links found 
through citations in Reyal et al. (2008). 
 Links for Data Set Download 
 ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/series/GSE7390/ 
 ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/series/GSE6532/ 
 ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/series/GSE3494/ 
 ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/series/GSE2603/ 
 ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/series/GSE1456/ 
The normalization software can only accept one chip type: HG-U133A. A program was written in 
Java by the authors to sort the *.CEL files into different folders based on chip type, as described by the 
DatHeader field in the .CEL file. Files with other types included HG-U133B and HG-U133AAofAv2, and 
were not used in this project. 
3.1.2. Software 
RMAExpress 
RMAExpress (http://rmaexpress.bmbolstad.com/) is an open-source, freely distributed library 
written by Benjamin Boldstad who is an author on a paper outlining the Robust Multi-chip Average 
procedure (Bolstad et al., 2003). This software implements the RMA normalization procedure, a three 
step process including background adjustment, quantile normalization and summarization. Use of the 
program consists of three steps. First, the user loads a *.CDF file describing the chip type. Then the user 
loads all of the *.CEL files that need to be normalized (*.CEL). Finally, the user selects Compute RMA 
Measures and the program will perform the normalization. The output of this process is a *.TXT file 
containing the normalized expression values, which are also log2 transformed. It is organized so that the 
genes form the rows and the microarrays form the columns. 
Cluster 3.0 
 Cluster 3.0 (http://bonsai.ims.u-tokyo.ac.jp/~mdehoon/software/cluster/software.htm) builds 
off of the original Cluster application written by Michael Eisen of Stanford University. It is capable of 
running various clustering algorithms on 2-dimensional data sets; these algorithms include hierarchical, 
k-means, self-organizing maps, and principal component analysis (Hoon, 2002). However, only the 
hierarchical clustering functionality was used. Like RMAExpress, this program is open source. 
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Java TreeView 
Java TreeView (http://jtreeview.sourceforge.net/) is an application developed by Alok Saldanha 
for the visualization of gene expression data. It chromatically displays the expression levels of all the 
genes for all the microarrays in a single block, and it allows the user to zoom in on a specific gene for 
more detailed observation. As with the previous programs, this is released under the GNU General 
Public License (Saldanha, 2003). 
dChip 
dChip (http://biosun1.harvard.edu/complab/dchip/) is a software package developed for 
handling Affymetrix microarrays. It is able to display and normalize *.CEL files, and performs more 
advanced functions like sample comparisons and hierarchical clustering (dChip: Introduction and 
Installation, 2007). In this project, dChip was used to extract lists of genes that are involved in specific 
functional groups for distance calculations. 
Weka 
 Weka (http://www.cs.waikato.ac.nz/ml/weka/) is a tool that features various algorithms for 
data mining. These algorithms are involved in procedures like preprocessing, classification, regression, 
clustering, association rules, and visualization (Witten & Frank, 2005). For this project, Weka was used 
for calculating distance metrics. 
3.2. Methods 
The flow chart of the process followed in this project is depicted below in Figure 5. The following 
subsections describe each step in detail.  
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Figure 5 – Flow Chart of Tools Used in this Project. 
3.2.1. Data Preprocessing  
 Normalization is necessary when comparing the results of different microarray chips, because it 
removes variation caused by the manufacture, preparation or experimental handling of the chip. That 
variation can obscure the interesting variations, which may exhibit important differences in the same 
genes between different microarrays. If the obscuring variations are not removed, improper results may 
be collected (Irizarry, et al., 2002). The procedure used to normalize Affymetrix chips is Robust Multichip 
Average (RMA) as implemented by RMAExpress. When the RMA’d data was written to a file the values 
were also converted to a log2 scale. This was done to accommodate algorithms that produce better 
results when applied to data that has been converted to a log2 scale. 
RMAExpress was used with the following settings: 
 Input: Raw Data (*.CDF, *.CEL files) 
 Settings: 
 Min Fold-Change < 20% 
 Percent Missing > 50% 
 Output: data.txt – normalized data 
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3.2.2. Clustering & Viewing the Clusters 
 Next, the normalized data was filtered and clustered. The filtering process used was 
implemented by Cluster 3.0. In Cluster 3.0, the only field modified for this project was the SW (Gene 
Vector) field. This filters genes based on how variable they are over the entire given data set, accepting 
genes with variation higher than the value set by the filter. An SW value of 0.5 will filter out fewer genes 
than with a value of 1.5. In this project, we initially used an SW value of 1.0. For latter experiments, we 
varied this value to observe changes in clustering results. Eventually, we decided to use 0.5 in order to 
work with a larger set of genes. 
 The clustering method used was an agglomerative hierarchical clustering. Clustering is a 
technique used in data mining to find groups of similar elements and measure their similarity. 
Hierarchical clustering begins with an arbitrary point and finds the next closest point. It then puts them 
into a cluster. The next closest point to this cluster’s centroid is then taken and if the cluster’s centroid is 
the closest point, a branch is created between the cluster and the point. If another point is closer than 
the original cluster’s centroid a new cluster is created. This continues for each point. See Figure 6 for a 
diagram of this process. 
 
Figure 6 – Diagram of Agglomerative Hierarchical Clustering. 
 The clustering was done using Cluster 3.0, which outputs a *.CDT file containing the genes 
(rows) and microarrays (columns) in order of similarity across genes and microarrays. Cluster 3.0 also 
outputs a *.ATR (contains information on microarray tree branches in the visualization) and *.GTR 
(contains information on gene tree branches) file. These files are then loaded into Java TreeView, which 
displays the dendrogram (a hierarchical tree) and relative expression values of the microarrays across 
the filtered genes. Each gene for each microarray is equivalent to one pixel in the grand representation. 
That pixel will be green if the expression for that gene is below median expression and red if it is above 
median expression; median expression in this case refers to the median expression value of the gene 
across the entire data set. The gene dendrogram is displayed with its branches extending horizontally 
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towards the data and the microarray dendrogram is displayed with its branches extending vertically 
towards the data. Figure 7 shows a screenshot of the visualization that Java TreeView provides. 
 
Figure 7 – Screenshot of Java TreeView GUI 
The following settings were used for Cluster 3.0 and Java TreeView: 
 Cluster 3.0 
 Input: data.txt 
 Settings: 
 Filter Data Tab: SW (Gene Vector) at 0.5  Apply Filter 
 Adjust Data Tab: Median Center Genes, then Median Center Arrays 
 Hierarchical Tab: Cluster Genes & Array  Centroid Linkage 
 Output: data.cdt, data.gtr, data.atr 
 Java TreeView 
 Input: data.cdt, data.gtr, data.atr 
3.2.3. Cluster Summarization 
 Cluster summarization refers to the grouping of sets of microarrays based on the similarity that 
is shown through Java TreeView. Basically, a branch node is selected and the children (microarrays) of 
that branch are grouped together. During the selection of branch nodes, correlation values were also 
taken into consideration. Correlation described how similar the microarrays in a given branch were, and 
we selected branches that had a correlation of 0.4 – 0.5. This was implemented through a java program 
that took input in the form of an *.ATR file and returned a list of microarray names corresponding to the 
children of a given node within the *.ATR file. More specifically, this was done by rebuilding the tree 
below that point and then recording each of the microarrays that made up the leaves of the tree. The 
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average and median centroids were obtained by taking a list of microarrays and a *.CDT file, and 
computing the average of the values of each gene for each of the given microarrays obtained from the 
*.CDT file. These were then written to a file, that mimicked a *.CDT file, so it could be displayed by Java 
TreeView. 
3.2.4. Unsupervised Ranking by Distance 
The distance between two points can be calculated in multiple ways. Two common distance 
functions are Euclidean and Manhattan. Expressions for the Euclidean and Manhattan distances are 
shown below:  
𝐸𝑢𝑐𝑙𝑖𝑑𝑒𝑎𝑛 𝒂,𝒃 =     𝑎𝑖 − 𝑏𝑖 2
𝑛
𝑖=1
 
𝑀𝑎𝑛𝑕𝑎𝑡𝑡𝑎𝑛 𝒂, 𝒃 =   𝑎𝑖 − 𝑏𝑖  
𝑛
𝑖=1
 
In both distance metrics, a and b represent the points, and n represents the number of 
dimensions. When given three points: if the distance between points a and b is lower than the distance 
between points a and c, then point b is closer, or more similar, to point a than point c according to that 
distance metric. 
Both methods of measuring distance were employed to rank similarity to a point of interest. A 
microarray was considered more similar to that point if the distance between the microarray and the 
point was relatively low. For these experiments the distance functions were calculated for each of the 
1056 samples to the point of interest. The Euclidean distance function used was implemented by Weka. 
The Manhattan distance function used was implemented by summing the absolute value of the 
difference for each gene between the microarray and a point of interest. This was implemented in a java 
program written by the authors. 
Once the distances between each microarray and the point of interest were calculated, the list 
of microarrays was ordered based on distance from smallest to largest. This was given as input to 
another java program which, using the *.CDT file of the initial clustering, ordered the microarrays based 
on the given ordering. By passing this *.CDT file into Java TreeView, we were able to observe the 
similarities and differences in gene expression levels with a new ordering of the microarrays. 
3.2.5. Supervised Ranking by Distance (Functional Gene Groups) 
In the previous ranking, the distances were calculated over every gene that passed through the 
filter. In order to generate better results, we decided to focus on groups of genes that are involved in 
specific functions. Using dChip, we extracted lists of genes involved in functions that may be relevant to 
Claudin-Low tumors (dChip: Introduction and Installation, 2007). The functional groups that we 
extracted were: apoptosis, basement membrane, cell-cell adhesion, cell communication, cell cycle, cell 
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proliferation, DNA repair, epidermis development, and tight junction. We then performed distance 
calculations within each of these functional groups between the microarrays and a point of interest. 
3.2.6. Other Computer Programs 
 Several other computer programs were written to facilitate the clustering and visualization 
process. Most of these were written by the author to parse or manipulate files for use with the tools 
mentioned above. These Java programs had various functions, including:  
 Filter and order genes in a *.CDT file based on a given gene list  
 Rename/move files; this was used to rename experiment files based on the study they came 
from 
 Move files based on the header of the raw *.CEL file 
 Add gene names and descriptions to a *.CDT file, replacing probe set names using a table that 
mapped probe sets to genes found in BRB ArrayTools. 
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4. Results 
The result of the initial hierarchical clustering was the discovery of 9 sub-clusters exhibiting 
different expression patterns. Furthermore, a highly correlated cluster of microarrays was discovered. 
These microarrays were actually derived from cell line (MDA-MB-231) that was originally derived from 
the pleural effusion of a breast cancer patient, and widely used in breast cancer research as an in vitro 
cell culture model for highly aggressive and invasive breast cancer. Because these cell lines are known to 
show an expression pattern similar to Claudin-Low tumors, we used their profiles as a proxy for Claudin-
Low tumor expression. The microarrays for these cell lines were grouped as cluster 1 and the other 
samples were compared to that cluster’s centroid without supervision and with supervision 
(incorporating functional gene groups). The final results were the discovery of two microarrays that 
were very similar to the cell lines, and 12 microarrays that were found to be similar to the cell lines in 
some aspects, but not in some aspects characteristic of Claudin-Low tumors.  
4.1. Initial Clustering 
After the data was run through RMA, log normalized, median centered by gene and by 
microarray, and filtered, the resulting genes were used to perform hierarchical clustering. The goal of 
clustering was to find groupings of microarrays that exhibited similar genetic expression. This would 
allow the classification of different groups and the discovery of microarrays exhibiting similar expression 
profiles like the recently discovered Claudin-Low subtype (Herschkowitz, et al., 2007).  
In the filtering step, 6,754 genes out of 22,283 passed the variability filter (SW > 0.5). This 
amount of filtering allowed analysis over a significant number of genes compared to those used in the 
Herschkowitz et al. (2007) profiling paper. These roughly 7,000 genes were used in the clustering shown 
in Figure 8. The horizontal dendrogram (rows) is a hierarchical clustering of the genes based on similar 
expression pattern throughout the samples. It was expected that the gene clustering would group genes 
that are regulated similarly and therefore likely have similar function. For example, some subtypes 
express a group of genes that induce a higher rate of proliferation while others do not. The genes in this 
set are regulated similarly; they are upregulated in the subtypes that have higher rates of proliferation 
but downregulated in those that do not. Since this group of genes shows a similar expression pattern 
they will show high correlation and are grouped together in the hierarchy. The vertical dendrogram 
shows a hierarchical clustering of the microarrays. Microarrays showing similar expression patterns will 
have a higher correlation and will be grouped together. 
The height of each branch of the dendrogram is based on the level of correlation between the 
two nodes it connects. A branch with little or no correlation between the nodes on the left and right will 
be very far in height from the colored pixels, while a very highly correlated branch will be very close in 
height to the pixels. The actual microarray expression values are seen in Figure 8 as the red and green 
pixels. Since all of the data was median centered by gene and by microarray, the color of the pixels 
illustrates whether it is above the median expression level (red) or below (green). Clusterings were also 
performed on a set of genes of greater variance (SW > 1.0, yielding around 700 genes) and on all of the 
genes (around 22,000). These clusterings were made for referential purposes and the microarrays and 
genes clustered similarly. They are not shown here. 
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One property of dendrograms generated from hierarchical clustering is that their branches can 
be flipped over a node. In other words, the left-most branch at a node can switch positions with the 
right-most branch without compromising the data. This property allowed us to manipulate the 
microarray orderings so that the arrays were ordered by cancer based on the genes that were expressed 
above median level. This ordering shows the progression of cancer from stem cells, to basal cells, and 
finally to luminal cells. The microarrays are labeled on the bottom of the image based on the 
developmental cell type for which they exhibit the expected gene expression pattern. SC stands for 
stem-like cells. In basal cells, keratins 5, 14, 6, and 17 exhibit above-median levels of expression while in 
luminal cells, keratins 8 and 18 exhibit above-median levels of expression. These keratins are marked in 
Figure 8 and are expected to be seen as red pixels for the given subtype where they are expected to 
exhibit above-median levels of expression.  
 
Figure 8 – Microarrays from Hierarchical Clustering Ordered by Development 
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4.2. Cluster Summarization 
Small clusters of microarrays can be merged into larger clusters based on their expression 
patterns; these larger clusters were chosen by hand based on homogeneity of the groups of microarrays 
as well as having a correlation value between 0.4 and 0.5. Figure 9 shows the average and median 
centroids of each of the nine resulting clusters. 
Average Centroids of Clusters    Median Centroids of Clusters 
          
Figure 9 – Average and Median Centroids of Cluster Summarizations 
The microarrays on the left region of Figure 8, which display very high intercluster correlation 
and fall under the SC development label, has a gene expression pattern similar to the Claudin-Low 
subtype. However, these microarrays are all from the same study. Additionally, they also have much 
higher and lower expression values than the median as shown by the brighter reds and greens in these 
samples. It was discovered through inspection of the study that these microarrays came from cell lines 
derived from a tumor sample that is the current best model for the Claudin-Low subtype. Specifically, 
the study was looking for tumor cells that metastasize to the lung (Minn, et al., 2005). All of these 
microarrays were added to the same cluster, cluster1, during cluster summarization, along with two 
other clinical samples (GSM178055 and GSM177944). These two clinical samples are considered 
Claudin-Low since they have such a high correlation with Claudin-Low cell line samples. The GEO 
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database identification values for these microarrays can be found in Table 1. Samples GSM49953 
through GSM50034 listed in Table 1 are the cell line microarrays. 
Table 1 - Cluster 1 Members (Claudin-Low cell lines and two clinical samples) 
GSM49953 GSM49954 GSM49955 GSM49956 
GSM49957 GSM50018 GSM50017 GSM50019 
GSM50020 GSM50021 GSM50024 GSM50034 
GSM50032 GSM50024 GSM50022 GSM50025 
GSM50027 GSM50026 GSM50028 GSM50030 
GSM50031 GSM50023 GSM50029 GSM50033 
GSM178055 GSM177944   
 
4.3. Ordering by Distance Metrics 
Once the information about the cell lines was available it became clear that while these are the 
best candidates for being Claudin-Low subtype breast cancer they are also already known to be of this 
subtype and their discovery is not novel. Instead, the microarrays of these cell lines were used as a 
comparison to find tumor samples that were most like the Claudin-Low subtype. This allowed us to use 
distance metrics to find more subtle relationships in the data set. Figure 10 shows the same data as 
Figure 8 (genes in the same order for both figures) but the microarrays are ordered by average 
Euclidean distance to all of the microarrays from cluster 1. Figure 11 and Figure 12 are the same as 
Figure 10, but the microarrays were ordered by Euclidean distance to the cluster 1 centroid and by 
Manhattan distance to the cluster 1 centroid respectively. 
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Figure 10 – Microarrays ordered based on Average Euclidean Distance to Cluster 1 Microarrays 
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Figure 11 – Microarrays Ordered by Euclidean Distance to Cluster 1 Centroid 
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Figure 12 – Microarrays Ordered by Manhattan Distance to Cluster 1 Centroid 
Figure 13 plots the Euclidean distances from each microarray to the cluster 1 centroid ordered 
smallest to largest. From this figure, it is clear that the cell lines listed in Table 1 made up the first 22 
points, marked with A in the diagram. However, an interesting result is that several other microarrays 
ranked closer to the cluster 1 centroid than the two non-cell-line microarrays that were part of cluster 1. 
A list of these microarrays can be seen in Table 2. The area where these samples can be seen in the 
graph is marked B in the diagram. These microarrays correspond with the microarrays before the first 
inflection point, about 0.9 in Figure 13, and the tumors they represent could be considered as more 
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Claudin-Low-like. However, after these microarrays were investigated closely, they were found to have 
too many basal markers to be considered purely Claudin-Low. Given that the Claudin-Low subtype is 
very similar to the basal subtype, this is not an entirely unexpected result. It is also possible that these 
tumors from these microarrays have sub-populations of Claudin-Low cells which skew the microarrays 
towards the Claudin-Low cell line’s centroid. 
 
Figure 13 – Values for Ordering by Manhattan Distance from Smallest to Largest 
Table 2 - Microarrays more similar than Cluster1 Clinical Microarrays by Manhattan Distance 
GSM107204 
GSM50067 
GSM178025 
GSM178079 
4.4. Ordering of Samples Considering Functional Gene Groups 
The genes can also be categorized into functional groups. This functional grouping of genes can 
be used to rank similarity in a more supervised manner. The average difference per gene in a given 
functional gene group between a microarray and the cluster 1 centroid was calculated. The average 
difference per gene can be conceptualized as the Manhattan distance for a given functional group 
divided by the number of genes in that functional group. The average value for each of the average 
difference per gene per gene group was calculated and used to order the microarrays from smallest to 
largest. Figure 14 shows this ordering. While it is not significantly different than the previous orderings, 
the values obtained seem to exaggerate the differences. The equation below shows the formula that 
was used to calculate this. In this formula 1,…,m each denote one functional gene group containing nj 
genes. Each of 1,…,nj refers to a gene within the functional group j. a and b each refer to a microarray 
and the subscripts refer to a gene value. 
𝑎𝑣𝑔. 𝑑𝑖𝑓𝑓. 𝑝𝑒𝑟 𝑔𝑒𝑛𝑒 𝑝𝑒𝑟 𝑓𝑢𝑛𝑐. 𝑔𝑒𝑛𝑒 𝑔𝑟𝑜𝑢𝑝(𝒂,𝒃) =  
 
  𝑎𝑗𝑖 − 𝑏𝑗𝑖  
𝑛𝑗
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Mathematically speaking, this analysis simply places equal weight on the differences between 
the genes of each functional gene group. Standard Manhattan distance can be normalized by the 
number of genes used to calculate it and would then be equal to the average difference per gene, 
placing equal weight on each gene. For the average difference per gene per gene group within a given 
gene group all of the genes hold equal weight and are condensed to one average. Thus no matter how 
many genes are in a given gene group the values can be compared since they have the same 
dimensionality. When the averages for each of the gene groups are averaged each gene groups have the 
same weight regardless of how many genes were used to calculate it. 
 
Figure 14 – Microarrays Ordered by Average Difference per Gene per Functional Gene Group 
Figure 15 is a graph of the values used to order by the average difference per gene per 
functional gene group (Figure 14). The inflection point is about 1.0 and again, corresponds roughly with 
one of the clinical samples from cluster 1. Again, several microarrays ranked closer than one of the 
clinical microarray samples that were grouped in cluster 1. These samples are listed in Table 3. 
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Figure 15 – Values for Ordering by Average Difference per Gene per Functional Gene Group 
Table 3 - Microarrays more similar than Cluster1 Clinical Samples by averaged average difference per gene per gene group 
GSM50067 
GSM107218 
GSM79189 
GSM177980 
GSM65845 
Another method of reordering the microarrays using the functional groups is to perform an 
order summarization. To do this, the microarrays are sorted in increasing order according to their 
Euclidean distances to the cluster 1 centroid on each of the functional groups. Each microarray gets a 
score equal to the sum of its placement within each ordering. For example, given three functional gene 
groups, a microarray might have the fifth, seventh, and tenth lowest distance from the cluster 1 
centroid, giving it an order summarization score of twenty-two. This was done using the functional gene 
groups as in Figure 14. Figure 16 shows a graph of the placement sums. The group with the smallest 
placement values and the next point after that are Claudin-Low cell lines. The point after that are two 
microarray samples; one of these is a clinical microarray that was grouped with cluster 1 and the other 
was a different microarray sample. The second clinical microarray that was added to cluster 1 is found 
ranked number 36 out of 1056. This sample corresponds with the inflection point seen in the graph 
below. This implies that the samples ranked from 24 to 36 all show very similar expression patterns to 
the Claudin-Low expression pattern when considered on a per gene group level. However, after 
investigation these 12 samples, listed in  
 
Table 4 is a set of the several microarrays found to rank more closely to cluster 1’s centroid than 
the two clinical tumor microarrays in the manhattan distance orderings and have already been 
investigated and found to be more basal-like than Claudin-Low like. 
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Figure 16 – Functional Gene Group Distance Order Summarization 
 
 
Table 4 - Microarrays more similar to Cluster 1 Samples by Order Summarization 
GSM79189 
GSM50037 
GSM65792 
GSM79270 
GSM150964 
GSM65857 
GSM50043 
GSM107107 
GSM79344 
GSM79340 
GSM65838 
A comparison of the per functional gene distances between the microarrays and cluster 1 can be 
seen by plotting the distance values for each group in a parallel coordinates graph (Figure 17). This 
method allows us to compare how similar each microarray is to the cluster 1 centroid by looking at one 
functional gene group at a time; the similarity between two microarrays over different functional groups 
may vary and we want to explore the possibility that certain functional groups are more useful in 
clustering Claudin-Low tumors than others. The collection of microarrays with the lowest values over 
each functional group are the cell line samples, listed in Table 1, which exhibited low overall distance in 
Figure 15. This collection is marked with an arrow in Figure 17. It is notable that there are no other 
microarrays that have a lower distance value in any of the functional groups than the cluster 1 
microarrays. 
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Figure 17 – Parallel Coordinates Graphing the Distance for each Functional Gene Group to Cluster 1’s  
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5. Discussion 
5.1. Existence of Claudin-Low Subtype 
In the comparative profiling of murine and human breast cancer tumors (Herschkowitz, et al., 
2007), roughly 2 to 3% of microarrays were found to exhibit genetic expression profiles similar to the 
new Claudin-Low subtype. In this project, it was expected that by analyzing a larger number of 
microarrays, this proportion of Claudin-Low like microarrays would be maintained in a meta-analysis of 
human breast cancer. Since this project’s data set contained 1056 microarrays of human breast cancer 
samples, 20 to 40 microarrays were expected to be identified as Claudin-Low. However, only two to 
three microarrays were found. There are several possible explanations for this result.  
The simplest reason is that there could be less Claudin-Low tumors found in Humans than in 
mice. Since the Minn breast cancer cell lines (Minn, et al., 2005) exhibit all of the characteristics of 
Claudin-Low tumors, and were derived by sorting human breast cancer tumors, it is known that Claudin-
Low cells do exist in humans.  
Second, Claudin-Low cells exhibit a very different morphology than other breast cancer cells; 
they are spindloid and metaplastic (Hennessy, et al., 2009). It is possible that when tumors were 
collected and classified, Claudin-Low tumors were clinically classified as non-breast tumors. This 
excludes them from the data sets used in this project. This is a problem often associated with survey 
studies, and is known as an ascertainment bias. 
Third, it is possible that the samples given in the dataset are not made up of one cell type. The 
image below, Figure 18, depicts tumor samples stained with hemotoxylin and eosin dyes that show cell 
morphology. These samples are examples of tumors and show that tumors do not contain only one type 
of cell. There is evidence within the genetic expression data that, while some of the tumors exhibit 
above-median expression of genes that are expected to be upregulated in Claudin-Low tumors, they 
also exhibit above-median expression of other genes that are characteristic of another subtype. This 
could be an artifact of tumor samples which contain some Claudin-Low cells and some of another 
subtype. A model explaining this follows: Claudin-Low tumors begin as stem cells and develop into cells 
of other stages without going through the intermediate stages. For example, a Claudin-Low tumor 
arises, originating from a stem-like cell, and when there are very few cells making up the tumor, one of 
the cells differentiates into a Luminal type cell and continues to divide. Some of the cells will be 
progenitors of the stem-like cells while the rest of the cells will be progenitors of the differentiated cell 
(luminal). The result of this would be a tumor where some of the cells are identified as Luminal while the 
others would be identified as Claudin-Low. Once the tumor cells achieve these morphologies (such as 
luminal or basal), they will exhibit characteristics similar to cancers of their respective cell types, despite 
their Claudin-Low origins. Another possible model of multi-type tumors is that the tumor arises in a 
developed cell (Luminal, for example) and then goes through an Epithelial-Mesenchymal Transition due 
to mutations or environmental factors. Both models are currently being considered by breast cancer 
research experts. The result here shows evidence for both of these models, but does not give stronger 
evidence for one over the other.  
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Even if Claudin-Low tumors were not a major subtype or if their numbers were much lower than 
those of other breast tumors, they continue to merit further research. With many of the luminal and 
basal tumors, the cancerous cells grow locally and are thus clinically maintainable. However, Claudin-
Low tumors are known to travel from their original environment, and since claudins are proteins vital for 
proper cell-cell communication, the spread of these cells can induce cancer formation in cells at other 
locations of the body, leading to metastasis.
 
Figure 18 - HE Stains of Mucine Breast Tumors exhibiting varying levels of splindloid morphology 
5.2. Clustering Summary Lead to Nine Subtypes 
 Sorlie et al. (2001) used roughly 80 tumor microarrays and stratified them into subclasses based 
on genetic expression and survival data. This led to five subtypes: basal-like, normal-breast-like, ERBB2-
overexpression, and two types of luminal-like. They note that the luminal type tumors can be stratified 
into at least two subtypes. Hu et al. (2006) tried to find a set of genes that can classify tumors into 
subtypes and found six subtypes; the sixth subtype was a novel type called IFN-like.  
 The cluster summarization of the initial hierarchical clustering found sets of microarrays that 
displayed similar expression profiles and showed a branch correlation of 0.4 to 0.5. This information was 
used to separate the microarrays into sub-clusters. Figure 9 shows the mean and median centroids of 
each of the nine sub-clusters. The resulting nine clusters had low enough correlation to each other that 
they can be considered different. This differs from the result of other subtype classifications, which 
produced five or six subtypes. Since these clusters are different enough, they may warrant further 
investigation to determine if more subtypes exist; a new subtype could be useful in determining 
prognosis and treatment.  
The goal of this project was not to find new classifications of breast cancer tumors, but some 
preliminary classification of the nine clusters can be offered. Cluster 1 was created using microarray data 
of the Minn cell lines, as well as two other microarrays (GSM178055 and GSM177944), which 
demonstrate similar genetic expression to the Minn cell lines. Cluster 1’s centroid was used throughout 
this project as the point of comparison in attempting to find the tumor microarrays that exhibit similar 
expression to Claudin-Low. Clusters 2 and 3 demonstrate above-median expression of keratins, which 
are expected to be upregulated in basal-like tumors despite demonstrating different levels of expression 
in other gene groups. The fact that the two basal-like clusters could be separated through correlation 
suggests that there may be a major sub-class within basal-like tumors; this is a previously undiscovered 
result. Cluster 4 has above-median expression of HER2. Clusters 5 and 6 have above-median expression 
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of luminally expressed keratins. Cluster 7 did not have any identifying genes over or under expressed. 
Clusters 8 and 9 exhibit normal breast tissue expression; these samples could have arisen due to tumor 
samples containing half basal-like cells and half luminal-like cells. Alternatively, the sample could have 
been taken improperly, and may actually contain normal breast cells as opposed to tumor cells.   
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